Psoriasis
Epidemiology and Classification of Psoriasis
Genetics and Pathogenesis of Psoriasis
Biologic Therapy for Psoriasis
TNF-Blocking Therapies
Arcutis submits sNDA for Zoryve foam 0.3% for scalp, body psoriasis
Arcutis has submitted a supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, according to a company press release.
High levels of saturated fatty acids associated with greater psoriasis severity
Patients with psoriasis, specifically those with a high BMI, had lower concentrations of polyunsaturated fatty acids and elevated concentrations of saturated fatty acid, which correlate to greater disease severity, according to a study.
Extra-articular Manifestations
Musculoskeletal Manifestations
Early life nutrition could impact psoriasis risk
A higher risk for developing psoriasis was found in subjects who were fed formula as infants compared with those who were breastfed for at least the first 4 months of life, according to a Swedish study.
Zasocitinib meets proof of concept in plaque psoriasis
Patients with psoriasis treated with higher doses of oral zasocitinib experienced greater improvement than those treated with placebo, according to a phase 2b study.